Stem Cell Authority Stock Performance
| SCAL Stock | USD 0.0001 0.00 0.00% |
The entity has a beta of -0.96, which indicates possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Stem Cell are expected to decrease slowly. On the other hand, during market turmoil, Stem Cell is expected to outperform it slightly. At this point, Stem Cell Authority has a negative expected return of -0.77%. Please make sure to validate Stem Cell's coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and rate of daily change , to decide if Stem Cell Authority performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Stem Cell Authority has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in January 2026. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Stem |
Stem Cell Relative Risk vs. Return Landscape
If you would invest 0.02 in Stem Cell Authority on September 25, 2025 and sell it today you would lose (0.01) from holding Stem Cell Authority or give up 50.0% of portfolio value over 90 days. Stem Cell Authority is currently does not generate positive expected returns and assumes 6.2017% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of pink sheets are less volatile than Stem, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Stem Cell Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Stem Cell's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Stem Cell Authority, and traders can use it to determine the average amount a Stem Cell's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.124
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SCAL |
Based on monthly moving average Stem Cell is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Stem Cell by adding Stem Cell to a well-diversified portfolio.
Stem Cell Fundamentals Growth
Stem Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Stem Cell, and Stem Cell fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Stem Pink Sheet performance.
| Return On Asset | 0.49 | |||
| Profit Margin | 0.55 % | |||
| Operating Margin | 0.55 % | |||
| Current Valuation | 9.15 M | |||
| Shares Outstanding | 348.71 M | |||
| Price To Earning | 2.00 X | |||
| Price To Sales | 1.05 X | |||
| Revenue | 3.33 M | |||
| Cash And Equivalents | 39.84 K | |||
| Total Debt | 675.1 K | |||
| Debt To Equity | 4.88 % | |||
| Earnings Per Share | 0.01 X | |||
| Total Asset | 3.99 M | |||
About Stem Cell Performance
By examining Stem Cell's fundamental ratios, stakeholders can obtain critical insights into Stem Cell's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Stem Cell is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Stem Cell Authority, Ltd., a technology development company, focuses on the collection and cryogenic preservation of stem cells. The companys technology enables birthing professionals with a stem cell preservation program to serve their maternity patients in the United States. Stem Cell operates under Medical Care Facilities classification in the United States and is traded on OTC Exchange.Things to note about Stem Cell Authority performance evaluation
Checking the ongoing alerts about Stem Cell for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Stem Cell Authority help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Stem Cell Authority generated a negative expected return over the last 90 days | |
| Stem Cell Authority has high historical volatility and very poor performance | |
| Stem Cell Authority has some characteristics of a very speculative penny stock |
- Analyzing Stem Cell's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Stem Cell's stock is overvalued or undervalued compared to its peers.
- Examining Stem Cell's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Stem Cell's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Stem Cell's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Stem Cell's pink sheet. These opinions can provide insight into Stem Cell's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Stem Pink Sheet
Stem Cell financial ratios help investors to determine whether Stem Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Stem with respect to the benefits of owning Stem Cell security.